Keryx Biopharmaceuticals (NASDAQ:KERX) stunned the market yesterday after releasing positive phase 3 data for its hyperphosphatemia drug Zerenex. Shares jumped around 75% after the news was released, and investors are still enjoying the newfound optimism surrounding this biotech company. Shares hopped another 40% today, but what caused this additional jump? What should investors watch for going forward? In this video, health care analyst Max Macaluso dives into these questions.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 09/18/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.